Finafloxacin
- Generic Name
- Finafloxacin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19FN4O4
- CAS Number
- 209342-40-5
- Unique Ingredient Identifier
- D26OSN9Q4R
- Background
Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
- Indication
Finafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.
- Associated Conditions
- Acute Otitis Externa
- Associated Therapies
- -
Fonseca Biosciences Secures Exclusive US Rights to XTORO® (finafloxacin otic
Fonseca Biosciences announced an agreement with MerLion Pharmaceuticals to market XTORO®, an FDA-approved treatment for acute otitis externa caused by Pseudomonas aeruginosa and Staphylococcus aureus. XTORO, with finafloxacin as the active ingredient, offers rapid symptom relief and broad-spectrum microbiological activity. Fonseca plans to distribute XTORO in the US by mid-2025, pending FDA approval of their application.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath